+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Adult Vaccines Global Market Report 2024

  • PDF Icon

    Report

  • 200 Pages
  • January 2024
  • Region: Global
  • The Business Research Company
  • ID: 5790504
The adult vaccines market size has grown strongly in recent years. It will grow from $21.48 billion in 2023 to $23.09 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth observed during the historical period can be attributed to various factors, including the increasing aging population, government-led vaccination programs, a growing awareness of preventive healthcare practices, ongoing vaccine development and innovation, and the impact of public health campaigns. These elements collectively contributed to the expansion and uptake of adult vaccines, reflecting a heightened focus on preventive measures and healthcare initiatives during that period.

The adult vaccines market size is expected to see strong growth in the next few years. It will grow to $32.13 billion in 2028 at a compound annual growth rate (CAGR) of 8.6%. The anticipated growth in the forecast period can be attributed to several key factors, including the emergence of new infectious threats, a heightened focus on immunization registries, the increasing threat of antimicrobial resistance, global initiatives for pandemic preparedness, a shift toward personalized vaccines, and an increased emphasis on maternal immunization. Major trends expected in the forecast period include the integration of digital health, technological advancements in vaccine production, collaborations between governments and pharmaceutical companies, innovations in vaccine delivery technologies, and the expansion of immunization programs. These trends collectively shape the evolving landscape of adult vaccines, reflecting a proactive approach to public health challenges.

The upward trajectory of the adult vaccine market is significantly influenced by the escalating prevalence of contagious diseases. Contagious diseases, which spread from person to person, underscore the critical need for vaccines in developing immunity against such illnesses. For instance, as of December 2022, the World Health Organization's COVID-19 dashboard reported 655 million COVID-19 infections since the virus emerged in 2019. Additionally, the global tuberculosis report by the World Health Organization noted a concerning rise in non-HIV-related tuberculosis deaths, escalating from 1.2 million in 2019 to 1.3 million in 2021. This surge in contagious diseases is a pivotal driver propelling the growth of the adult vaccines market.

The surge in healthcare expenditure has significantly bolstered the adult vaccine market. Healthcare expenditure encompasses the total cost of healthcare services provided to a population and often leads to amplified funding for medical research and development. Increased investments in vaccination programs and expanded access to vaccines are vital for mitigating preventable diseases and enhancing overall population health. Moreover, adult vaccination programs can yield substantial cost savings by curbing healthcare utilization and reducing the necessity for costly treatments. Notably, India's public expenditure on healthcare surged to 2.1% of GDP in 2021-22 from 1.8% in 2020-21, as highlighted in the Economic Survey of 2022. This increased healthcare expenditure has positively influenced the growth trajectory of the adult vaccine market.

Product innovation emerges as a pivotal trend driving the evolution of the adult vaccines market. Major industry players are introducing innovative products to fortify their market presence. For instance, in August 2022, GSK, a UK-based biopharma company, partnered with IQVIA, an India-based global provider of advanced analytics and clinical research services, to launch Vaccine Track. This pioneering data trend platform aims to enhance adult vaccination efforts nationwide by providing real-time, pertinent data trends that focus on improving public health initiatives. The advent of such innovative tools underscores the industry's commitment to leveraging data and technology to advance adult vaccination strategies and address prevailing healthcare challenges.

Prominent players within the adult vaccine market are emphasizing strategic collaborations aimed at the development and commercialization of personalized cancer vaccines. These collaborations, centered on mutual objectives, are pivotal business relationships between multiple companies. For instance, in October 2022, Merck & Co., Inc., an American multinational pharmaceutical company, partnered with Moderna, a US-based pharmaceutical and biotechnology company, to collectively advance and commercialize the personalized cancer vaccine mRNA-4157/V940. Under their existing collaboration and license agreement, both entities will collaborate on the development and commercialization of mRNA-4157/V940, which is currently undergoing assessment in a Phase 2 clinical trial conducted by Moderna. This vaccine is being evaluated alongside KEYTRUDA, Merck's anti-PD-1 therapy, as an adjuvant treatment for high-risk melanoma patients.

In August 2022, GSK, a UK-based pharmaceutical giant, acquired Affinivax, Inc., a US-based clinical-stage biopharmaceutical company, in a deal of undisclosed value. This strategic acquisition aligns with GSK's broader strategy of bolstering its portfolio in specialty medicines and vaccines, particularly focusing on innovative vaccine candidates for pneumococcal disease. Affinivax, Inc., known for its pioneering work in next-generation pneumococcal vaccines and adult vaccines based on the Multiple Antigen Presenting System (MAPS) platform technology, is expected to complement GSK's efforts in advancing cutting-edge vaccine solutions. This strategic move underscores GSK's commitment to driving advancements in adult vaccines and strengthening its position within the healthcare landscape.

Major companies operating in the adult vaccines market report are GlaxoSmithKline PLC, Merck & Co, Sanofi Pasteur, Pfizer Inc, Commonwealth Serum Laboratories Limited, Johnson & Johnson, Serum Institute of India, AstraZeneca PLC, Novartis AG, Protein Sciences Corporation, Emergent BioSolutions Inc., Bavarian Nordic A/S, Dynavax Technologies Corporation, Novavax Inc, Medimmune, BioNTech SE, Moderna, Inovio Pharmaceuticals, Sinovac, Valneva Se, Bharat Biotech, Biological E Limited, Panacea Biotec, Shenzhen Kangtai Biological Products, Beijing Tiantan Biological Products, Hualan Biological Engineering, Chengdu Institute of Biological Products, Bharat Biotech International Limited, Protein Sciences Corporation, Takeda Pharmaceutical Company Limited.

North America was the largest region in the adult vaccines market in 2023. Asia-Pacific is expected to be the fastest-growing region in the adult vaccines market during the forecast period. The regions covered in the adult vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adult vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of adult vaccines include monovalent and multivalent options. A monovalent vaccine contains the mRNA component of a single virus, triggering an immune response against a specific antigen. Various technologies are employed in the development of adult vaccines, including live attenuated vaccines, inactivated viral or bacterial vaccines, toxoid vaccines, recombinant vaccines, and conjugate vaccines. These vaccines find applications in preventing diseases such as influenza, diphtheria, pertussis, tetanus (dPT), human papillomavirus, shingles (zoster), pneumococcal disease, and hepatitis. Healthcare firms and hospitals are key users of these vaccines.

The adult vaccines market research report is one of a series of new reports that provides adult vaccines market statistics, including adult vaccines industry global market size, regional shares, competitors with a adult vaccines market share, detailed adult vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the adult vaccines industry. This adult vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Adult Vaccines Market Characteristics3. Adult Vaccines Market Trends and Strategies
4. Adult Vaccines Market - Macro Economic Scenario
4.1. Impact of High Inflation on the Market
4.2. Ukraine-Russia War Impact on the Market
4.3. COVID-19 Impact on the Market
5. Global Adult Vaccines Market Size and Growth
5.1. Global Adult Vaccines Market Drivers and Restraints
5.1.1. Drivers of the Market
5.1.2. Restraints of the Market
5.2. Global Adult Vaccines Historic Market Size and Growth, 2018-2023, Value ($ Billion)
5.3. Global Adult Vaccines Forecast Market Size and Growth, 2023-2028, 2033F, Value ($ Billion)
6. Adult Vaccines Market Segmentation
6.1. Global Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Monovalent
  • Multivalent
6.2. Global Adult Vaccines Market, Segmentation by Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Live Attenuated Vaccines
  • Inactivated Viral or Bacterial Vaccines
  • Toxoid Vaccines
  • Recombinant Vaccines
  • Conjugate Vaccines
6.3. Global Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Influenza
  • DPT
  • Human Papillomavirus
  • Zoster
  • Pneumococcal
  • Hepatitis
6.4. Global Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Healthcare Firms
  • Hospitals
7. Adult Vaccines Market Regional and Country Analysis
7.1. Global Adult Vaccines Market, Split by Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Adult Vaccines Market, Split by Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Adult Vaccines Market
8.1. Asia-Pacific Adult Vaccines Market Overview
Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Adult Vaccines Market
9.1. China Adult Vaccines Market Overview
9.2. China Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Adult Vaccines Market
10.1. India Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Adult Vaccines Market
11.1. Japan Adult Vaccines Market Overview
11.2. Japan Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Adult Vaccines Market
12.1. Australia Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Adult Vaccines Market
13.1. Indonesia Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Adult Vaccines Market
14.1. South Korea Adult Vaccines Market Overview
14.2. South Korea Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Adult Vaccines Market
15.1. Western Europe Adult Vaccines Market Overview
15.2. Western Europe Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Adult Vaccines Market
16.1. UK Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Adult Vaccines Market
17.1. Germany Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Adult Vaccines Market
18.1. France Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Adult Vaccines Market
19.1. Italy Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Adult Vaccines Market
20.1. Spain Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Adult Vaccines Market
21.1. Eastern Europe Adult Vaccines Market Overview
21.2. Eastern Europe Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Adult Vaccines Market
22.1. Russia Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Adult Vaccines Market
23.1. North America Adult Vaccines Market Overview
23.2. North America Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Adult Vaccines Market
24.1. USA Adult Vaccines Market Overview
24.2. USA Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Adult Vaccines Market
25.1. Canada Adult Vaccines Market Overview
25.2. Canada Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Adult Vaccines Market
26.1. South America Adult Vaccines Market Overview
26.2. South America Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Adult Vaccines Market
27.1. Brazil Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Adult Vaccines Market
28.1. Middle East Adult Vaccines Market Overview
28.2. Middle East Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Adult Vaccines Market
29.1. Africa Adult Vaccines Market Overview
29.2. Africa Adult Vaccines Market, Segmentation by Vaccine, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Adult Vaccines Market, Segmentation by Application , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Adult Vaccines Market, Segmentation by End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Adult Vaccines Market Competitive Landscape and Company Profiles
30.1. Adult Vaccines Market Competitive Landscape
30.2. Adult Vaccines Market Company Profiles
30.2.1. GlaxoSmithKline PLC
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Merck & Co
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. Sanofi Pasteur
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. Pfizer Inc
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. Commonwealth Serum Laboratories Limited
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Global Adult Vaccines Market Competitive Benchmarking32. Global Adult Vaccines Market Competitive Dashboard33. Key Mergers and Acquisitions in the Adult Vaccines Market
34. Adult Vaccines Market Future Outlook and Potential Analysis
34.1 Adult Vaccines Market in 2028 - Countries Offering Most New Opportunities
34.2 Adult Vaccines Market in 2028 - Segments Offering Most New Opportunities
34.3 Adult Vaccines Market in 2028 - Growth Strategies
34.3.1 Market Trend Based Strategies
34.3.2 Competitor Strategies
35. Appendix
35.1. Abbreviations
35.2. Currencies
35.3. Historic and Forecast Inflation Rates
35.4. Research Inquiries
35.5. About the Analyst
35.6. Copyright and Disclaimer

Executive Summary

Adult Vaccines Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on adult vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for adult vaccines? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This adult vaccines market global report answers all of these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
  • The impact of higher inflation in many countries and the resulting spike in interest rates.
  • The continued but declining impact of COVID-19 on supply chains and consumption patterns.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Vaccine Type: Monovalent; Multivalent

2) By Technology: Live Attenuated Vaccines; Inactivated Viral or Bacterial Vaccines; Toxoid Vaccines; Recombinant Vaccines; Conjugate Vaccines

3) By Application: Influenza; DPT; Human Papillomavirus; Zoster; Pneumococcal; Hepatitis

4) By End Users: Healthcare Firms; Hospitals

Companies Mentioned: GlaxoSmithKline PLC; Merck & Co; Sanofi Pasteur; Pfizer Inc; Commonwealth Serum Laboratories Limited

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • GlaxoSmithKline PLC
  • Merck & Co
  • Sanofi Pasteur
  • Pfizer Inc
  • Commonwealth Serum Laboratories Limited
  • Johnson & Johnson
  • Serum Institute of India
  • AstraZeneca PLC
  • Novartis AG
  • Protein Sciences Corporation
  • Emergent BioSolutions Inc.
  • Bavarian Nordic A/S
  • Dynavax Technologies Corporation
  • Novavax Inc
  • Medimmune
  • BioNTech SE
  • Moderna
  • Inovio Pharmaceuticals
  • Sinovac
  • Valneva Se
  • Bharat Biotech
  • Biological E Limited
  • Panacea Biotec
  • Shenzhen Kangtai Biological Products
  • Beijing Tiantan Biological Products
  • Hualan Biological Engineering
  • Chengdu Institute of Biological Products
  • Bharat Biotech International Limited
  • Protein Sciences Corporation
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...